Key Highlights
- SELLAS Life Sciences (NASDAQ:SLS) was trading down 13.98% at USD 15.44 on Thursday, November 19, 2026, in intraday market data, a day after launching an underwritten public offering of common stock.
- The proposed offering is USD 150.0 million, announced on November 17, 2026, with underwriters holding a 30-day option for up to USD 22.5 million more, and all shares sold by the company.
- J.P. Morgan and TD Cowen are joint book-running managers, and the sale uses a Form S-3 shelf registration filed on March 20, 2026, which became effective automatically on filing.
- The company held USD 134.7 million of cash at September 30, 2026, with 203,527,833 shares outstanding, before the new shares and any underwriter option are counted.
Offering Follows a Sharp Rally on Phase 3 Data
SELLAS Life Sciences (NASDAQ:SLS) was trading at USD 15.44, down 13.98%, in intraday market data on Thursday, November 19, 2026. That implies a prior close near USD 17.95 (calculated). The pullback comes after the company announced on November 17, 2026 that its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia met its overall survival goal, with median survival of 24.0 months against 14.7 months for best available treatment, a hazard ratio of 0.59 and a p-value of 0.035. Later that day the company launched the offering. The release did not state a price per share, and no final pricing was confirmed in the searches for this article, so the discount to the market remains unknown.
How a Follow-On Sale Weighs on the Share Price
SELLAS is a late-stage biopharmaceutical company developing cancer therapies. Its lead candidate, galinpepimut-S, targets the WT1 protein and is licensed from Memorial Sloan Kettering Cancer Center, while a second program, SLS009 (tambiciclib), is a CDK9 inhibitor for leukemia patients with unfavorable prognostic factors. Because every share is being sold by the company, the offering adds new shares and spreads existing ownership across a larger base. Underwriters usually price such deals below the last trade to clear the whole block, which often pressures the stock on the day. The USD 150.0 million size equals roughly 4% of a Market Value near USD 3.1 billion (calculated from 203.5 million shares at USD 15.44, excluding new shares). The release did not say how the proceeds will be used.
Cash, Regulatory Timeline and What Could Go Wrong
SELLAS reported USD 134.7 million of cash and a third-quarter net loss of USD 10.1 million on November 12, 2026. The company has said it plans to meet the FDA about an accelerated filing strategy and is preparing a Biologics License Application for the first half of 2027. Fresh Capital would fund that work, but risks remain: the REGAL study was open-label, the p-value sits only modestly below 0.05, the sample was 126 patients, and regulators may ask for more data. The offering is also subject to market conditions, so its timing, size and terms are not assured. A small number of trades can move such a price, and quoted moves can reverse.
Where Things Stand
It is down because the company launched a large Equity raise right after a huge rally. SELLAS Life Sciences (NASDAQ:SLS) is selling new shares, the final price is not yet confirmed, and holders are weighing dilution against the funding it brings for the REGAL filing path. The Phase 3 result itself has not changed. Next markers are the offering's pricing terms, the FDA meeting on an accelerated filing, the secondary REGAL analyses, a medical conference presentation and the planned application in the first half of 2027.


_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)

Please wait processing your request...